{"meta":{"totalResults":6,"from":0},"results":[{"aliases":[{"type":"ChemicalStructureName","name":"3'-5'-dichloromethotrexate"},{"type":"Abbreviation","name":"DCM"},{"type":"Synonym","name":"dichloroamethopterin"},{"type":"ChemicalStructureName","name":"3',5'-dichloroamethopterin"},{"type":"ChemicalStructureName","name":"amethopterin, 3',5'-dichloro"},{"type":"ChemicalStructureName","name":"glutamic Acid, N-{3,5-dichloro-4-{[(2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl}-"},{"type":"ChemicalStructureName","name":"glutamic Acid, N-{3,5-dichloro-4-{[(2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl}-L- (8CI)"},{"type":"ChemicalStructureName","name":"L-glutamic Acid, N-{3,5-dichloro-4-{[(2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl}-(9CI)"},{"type":"Synonym","name":"methotrexate, dichloro"},{"type":"ChemicalStructureName","name":"N-[3,5-dichloro-4-[(2,4-diamino-6-pteridinylmethyl)methylamino]benzoyl] Glutamic Acid"},{"type":"INDCode","name":"3168"},{"type":"NSCNumber","name":"29630"},{"type":"CASRegistryName","name":"528-74-5"}],"definition":{"html":"A chlorinated methotrexate derivative.  Dichloromethotrexate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylates and inhibiting DNA and RNA synthesis.  This agent is metabolized and excreted by the liver.","text":"A chlorinated methotrexate derivative.  Dichloromethotrexate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylates and inhibiting DNA and RNA synthesis.  This agent is metabolized and excreted by the liver."},"drugInfoSummaryLink":null,"nciConceptId":"C966","nciConceptName":"Dichloromethotrexate","termId":39217,"name":"dichloromethotrexate","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"dichloromethotrexate"},{"aliases":[{"type":"ChemicalStructureName","name":"4-amino-10-methylfolic acid"},{"type":"ChemicalStructureName","name":"4-amino-4-deoxy-10-methylpteroyl-L-glutamic acid"},{"type":"ObsoleteName","name":"Abitrexate"},{"type":"Synonym","name":"alpha-methopterin"},{"type":"Synonym","name":"amethopterin"},{"type":"ForeignBrandName","name":"Brimexate"},{"type":"CodeName","name":"CL 14377"},{"type":"CodeName","name":"CL-14377"},{"type":"ForeignBrandName","name":"Emtexate"},{"type":"ForeignBrandName","name":"Emthexat"},{"type":"ForeignBrandName","name":"Emthexate"},{"type":"ForeignBrandName","name":"Farmitrexat"},{"type":"ForeignBrandName","name":"Fauldexato"},{"type":"ObsoleteName","name":"Folex"},{"type":"ObsoleteName","name":"Folex PFS"},{"type":"ForeignBrandName","name":"Lantarel"},{"type":"ForeignBrandName","name":"Ledertrexate"},{"type":"ForeignBrandName","name":"Lumexon"},{"type":"ForeignBrandName","name":"Maxtrex"},{"type":"ForeignBrandName","name":"Medsatrexate"},{"type":"ForeignBrandName","name":"Metex"},{"type":"ForeignBrandName","name":"Methoblastin"},{"type":"Synonym","name":"methotrexate LPF"},{"type":"Synonym","name":"methotrexate methylaminopterin"},{"type":"Synonym","name":"methotrexatum"},{"type":"Synonym","name":"metotrexato"},{"type":"ForeignBrandName","name":"Metrotex"},{"type":"ObsoleteName","name":"Mexate"},{"type":"ObsoleteName","name":"Mexate-AQ"},{"type":"Abbreviation","name":"MTX"},{"type":"ChemicalStructureName","name":"N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid"},{"type":"ForeignBrandName","name":"Novatrex"},{"type":"Synonym","name":"Rheumatrex"},{"type":"ForeignBrandName","name":"Texate"},{"type":"ForeignBrandName","name":"Tremetex"},{"type":"ForeignBrandName","name":"Trexeron"},{"type":"ForeignBrandName","name":"Trixilem"},{"type":"CodeName","name":"WR-19039"},{"type":"USBrandName","name":"Jylamvo"}],"definition":{"html":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","text":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear."},"drugInfoSummaryLink":null,"nciConceptId":"C642","nciConceptName":"Methotrexate","termId":817181,"name":"methotrexate","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"methotrexate"},{"aliases":[{"type":"Synonym","name":"sodium methotrexate"},{"type":"USBrandName","name":"Trexall"},{"type":"USBrandName","name":"Xatmep"},{"type":"CASRegistryName","name":"7413-34-5"}],"definition":{"html":"The sodium salt of methotrexate, an antimetabolite with antineoplastic and immunomodulating properties.  Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties.","text":"The sodium salt of methotrexate, an antimetabolite with antineoplastic and immunomodulating properties.  Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/methotrexate-sodium","text":"Methotrexate Sodium (Cancer Treatment)"},"nciConceptId":"C1735","nciConceptName":"Methotrexate Sodium","termId":41719,"name":"methotrexate sodium","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"methotrexate-sodium"},{"aliases":[{"type":"Abbreviation","name":"MTX-e TI"},{"type":"Synonym","name":"MTX/epi gel"},{"type":"Synonym","name":"methotrexate-epinephrine therapeutic implant"},{"type":"Synonym","name":"methotrexate/epi"}],"definition":{"html":"An injectable collagen matrix gel containing the antimetabolite methotrexate and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of methotrexate into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of methotrexate and increasing its anti-tumor activity. Intratumoral injection of methotrexate combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects.","text":"An injectable collagen matrix gel containing the antimetabolite methotrexate and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of methotrexate into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of methotrexate and increasing its anti-tumor activity. Intratumoral injection of methotrexate combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects."},"drugInfoSummaryLink":null,"nciConceptId":"C17876","nciConceptName":"Methotrexate-E Therapeutic Implant","termId":41858,"name":"methotrexate-e therapeutic implant","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"methotrexate-e-therapeutic-implant"},{"aliases":[{"type":"Abbreviation","name":"MTX-ATMP"}],"definition":{"html":"A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity.","text":"A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity."},"drugInfoSummaryLink":null,"nciConceptId":"C125656","nciConceptName":"Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles","termId":778520,"name":"methotrexate-encapsulating autologous tumor-derived microparticles","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"methotrexate-encapsulating-autologous-tumor-derived-microparticles"},{"aliases":[{"type":"Synonym","name":"M-VAC regimen"},{"type":"Synonym","name":"methotrexate-vinblastine-adriamycin-cisplatin regimen"},{"type":"Synonym","name":"methotrexate-vinblastine-doxorubicin-cisplatin regimen"},{"type":"Synonym","name":"methotrexate-vinblastine sulfate-doxorubicin hydrochloride-cisplatin regimen"}],"definition":{"html":"A regimen consisting of methotrexate, vinblastine, doxorubicin, and cisplatin used for the treatment of advanced-stage  urothelial carcinoma, including bladder  cancer.\n","text":"A regimen consisting of methotrexate, vinblastine, doxorubicin, and cisplatin used for the treatment of advanced-stage  urothelial carcinoma, including bladder  cancer.\n"},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/MVAC","text":"MVAC"},"nciConceptId":"C63486","nciConceptName":"MVAC Regimen","termId":790968,"name":"MVAC regimen","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"mvac-regimen"}],"links":null}